Neurofibromatosis - Pipeline Review, Q2 2011

Date: May 1, 2011
Pages: 57
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: N66239BA7B1EN
Leaflet:

Download PDF Leaflet

Neurofibromatosis - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Neurofibromatosis - Pipeline Review, Q2 2011', provides an overview of the Neurofibromatosis therapeutic pipeline. This report provides information on the therapeutic development for Neurofibromatosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neurofibromatosis. 'Neurofibromatosis - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Neurofibromatosis.
  • A review of the Neurofibromatosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Neurofibromatosis pipeline on the basis of therapeutic class, route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Neurofibromatosis.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Neurofibromatosis pipeline depth and focus of Neurofibromatosis therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neurofibromatosis Overview
Therapeutics Development
An Overview of Pipeline Products for Neurofibromatosis
Neurofibromatosis Therapeutics under Development by Companies
Neurofibromatosis Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Neurofibromatosis Therapeutics - Products under Development by Companies
Neurofibromatosis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Neurofibromatosis Therapeutics Development
PTC Therapeutics, Inc.
Nexgenix Pharmaceuticals, LLC
Neurofibromatosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
PTC299 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rapamycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pak Inhibitors - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NX101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rapamycin + Skincerity - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lovastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BAY 43-9006 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lapatinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methotrexate + Vinblastine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pirfenidone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PEG-interferon alfa-2a - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PEG-interferon alfa-2a - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Doxorubicin + Etoposide + Ifosfamide + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PEG-Intron - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pegintron - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pirfenidone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
R115777 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sirolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sirolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
filgrastim + doxorubicin hydrochloride + etoposide + ifosfamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
filgrastim + doxorubicin hydrochloride + etoposide + ifosfamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peg-Interferon alpha-2b + Celebrex + Temodar + Vincristine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZD2171 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Neurofibromatosis, Q2 2011
Products under Development for Neurofibromatosis – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Comparative Analysis by Pre-Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
PTC Therapeutics, Inc., 2011
Nexgenix Pharmaceuticals, LLC, 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011

LIST OF FIGURES

Number of Products under Development for Neurofibromatosis, Q2 2011
Products under Development for Neurofibromatosis – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Pre-Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011
Neurofibromatosis - Pipeline Review, Q4 2010 US$ 450.00 Nov, 2010 · 50 pages
Neurofibromatoses – Pipeline Review, H2 2012 US$ 1,800.00 Nov, 2012 · 79 pages
Oral Mucositis - Pipeline Review, H2 2014 US$ 1,800.00 Aug, 2014 · 99 pages
Chronic Drooling - Pipeline Review, Q4 2010 US$ 450.00 Nov, 2010 · 50 pages

Ask Your Question

Neurofibromatosis - Pipeline Review, Q2 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: